Alvotech Completes $108 Million Convertible Bond Offering to Drive R&D and Biosimilar Launches

Alvotech ( (ALVO) ) has issued an update.

Alvotech successfully completed the placement of $108 million senior unsecured convertible bonds on December 17, 2025, in a highly oversubscribed offering scheduled to settle by December 22, 2025. This funding strengthens the company’s ability to scale manufacturing and support product launches, aligning with its goal to invest $250 million in R&D in 2026, including launching four new global biosimilars. The issuance reinforces the company’s market positioning and commitment to advancing access to affordable biologic treatments, while reflecting robust confidence from international professional investors.

The most recent analyst rating on (ALVO) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.

Spark’s Take on ALVO Stock

According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.

Alvotech’s overall stock score is driven by financial instability, bearish technical indicators, and regulatory challenges impacting short-term outlook. While strategic investments and historical growth are positives, significant risks remain.

To see Spark’s full report on ALVO stock, click here.

More about Alvotech

Alvotech is a biotech company specializing in the development and manufacturing of biosimilar medicines, aiming to deliver cost-effective biologic treatments globally. With five biosimilars already approved for conditions such as autoimmune disorders and eye diseases, the company boasts a pipeline of 30 biosimilar candidates while maintaining strategic partnerships across various markets, including the U.S., Europe, and Asia.

Average Trading Volume: 580,123

Technical Sentiment Signal: Sell

Current Market Cap: $1.47B

For a thorough assessment of ALVO stock, go to TipRanks’ Stock Analysis page.